• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Eye care portfolio?


<











Some has beens and a definitely it abicipar. Nice job with that. Between Beovu and Abicipar, think of the $$ blown on two highly touted next generation anti vegf’s.
 




Similar threads

Replies
214
Views
30K
Replies
2
Views
3K
Allergan
anonymous
Replies
6
Views
5K